97193 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders
#302Methods for improving safety of blood-brain barrier transport
#303Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#304Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#305Methods for generating bispecific functional agents
#306Anti-transferrin receptor antibodies with tailored affinity
#307Binding molecules with modified J-chain
#308Anti-alpha-synuclein antibodies and methods of use
#309Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#310Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
#311Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
#312Anti-transferrin receptor antibodies and methods of use
#313Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
#314Anti-transferrin receptor antibodies and methods of use
#315TfR selective binding compounds and related methods
#316Polymalic acid-based nanobiopolymer compositions
#317Drug delivery of temozolomide for systemic based treatment of cancer
#318TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES
#319Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#320pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
#321Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
#322METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIER
#323ANTI-BRDU ANTIBODIES AND METHODS OF USE
#324USE OF TGF-BETA ANTAGONISTS OF TREAT TYPE-2 DIABETES
#325Anti-alpha-synuclein antibodies and methods of use
#326Monovalent blood brain barrier shuttle modules
#327Anti-human transferrin receptor antibody that passes through blood-brain barrier
#328Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
#329Molecular constructs for treating central nervous system diseases
#330Molecular constructs for treating infectious diseases
#331Molecular constructs with targeting and effector moieties for treating infectious diseases
#332Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
#333Peptide core-based multi-arm linkers for treating infectious diseases
#334Peptide core-based multi-arm linkers for treating central nervous system diseases
#335Peptide core-based multi-arm linkers and their applications
#336Recombinant polypeptide production methods
#337Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#338MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGENS, AND USES THEREOF
#339Drug delivery of temozolomide for systemic based treatment of cancer
#340THERAPEUTIC FUSION PROTEIN
#341BLOOD-BRAIN BARRIER (BBB) PENETRATING DUAL SPECIFIC BINDING PROTEINS FOR TREATING BRAIN AND NEUROLOGICAL DISEASES
#342METHODS FOR IMPROVING SAFETY OF BLOOD-BRAIN BARRIER TRANSPORT
#343Low affinity blood brain barrier receptor antibodies and uses therefor
#344Method for the production and selection of molecules comprising at least two different entities and uses thereof
#345Antibody capable of specifically recognizing transferrin receptor
#346PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF
#347Internalizing ErbB2 antibodies
#348Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
#349Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#350USE OF TRANSFERRIN RECEPTOR ANTAGONIST FOR THE TREATMENT OF THALASSEMIA
#351Anti-alpha-synuclein antibodies and methods of use
#352Anti-transferrin receptor antibodies and methods of use
#353Methods and compositions for generating bioactive assemblies of increased complexity and uses
#354Method of boosting the immune response in neonates
#355Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
#356Bispecific intracellular delivery vehicles
#357Synthetic antibodies
#358Polymalic acid-based nanobiopolymer compositions
#359Antibody capable of specifically recognizing transferrin receptor
#360Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
#361Internalizing erbB2 antibodies
#362Anti-human transferrin receptor antibody and uses thereof
#363Methods and compositions for generating bioactive assemblies of increased complexity and uses
#364ANTIBODIES DIRECTED AGAINST THE TRANSFERRIN RECEPTOR AND USES THEREOF FOR IMMUNOTHERAPY OF IRON-DEPENDENT TUMOURS
#365Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
#366Drug delivery of temozolomide for systemic based treatment of cancer
#367Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
#368LOW AFFINITY BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND USES THEREFOR
#369Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
#370Bispecific intracellular delivery vehicles
#371Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
#372BLOOD-BRAIN BARRIER TARGETING ANTIBODIES
#373COMPOUND AND METHOD FOR REGULATING PLASMINOGEN ACTIVATION AND CELL MIGRATION
#374Internalizing ErbB2 antibodies
#375Methods and compositions for generating bioactive assemblies of increased complexity and uses
#376Synthetic Antibodies
#377Methods for diagnosing CNS disorders with fusion antibodies that cross the blood-brain barrier in both directions
#378Blood-brain barrier targeting anti-bodies
#379Transferrin receptor antibodies
#380Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
#381COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE
#382Methods and compositions for generating bioactive assemblies of increased complexity and uses
#383Fusion proteins for delivery of GDNF to the CNS
#384Methods of selecting internalizing antibodies
#385Antibody-avidin fusion proteins as cytotoxic drugs
#386Anti TfR antibody
#387Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
#388Fusion antibodies that cross the blood-brain barrier in both directions
#389Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
#390Internalizing ErbB2 antibodies
#391Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
#392Methods and compositions for generating bioactive assemblies of increased complexity and uses
#393Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
#394Compound and method for regulating plasminogen activation and cell migration
#395Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
#396Transferrin receptor antibodies
#397Method and compositions for treating diseases targeting CD71
#398IgA antibody protein as a cytotoxic drug
#399Transgenically produced fusion proteins
#400Cell-specific retroviral vectors with antibody domains and method for the production thereof for selective gene transfer
#401Delivery of enzymes to the brain
#402Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
#403Methods of selecting internalizing antibodies
#404Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
#405Nucleic acid-polypeptide compositions and methods of inducing exon skipping